Abiopharma

🔍 Divisadero Street Capital Management, LP (Executive)

Company: Lifeway Foods, Inc. (LWAY)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 195,616 shares of Common Stock, No Par Value at $24.8729 per share (Direct)
  Date: 2026-08-13 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,297,156.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 15,000 shares of Common Stock, No Par Value at $24.6901 per share (Direct)
  Date: 2026-08-14 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,312,156.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 35,952 shares of Common Stock, No Par Value at $24.7809 per share (Direct)
  Date: 2026-08-17 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,348,108.00 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.5375 - $25.4022. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in this footnote to this Form 4.
• F2: The reported securities are owned directly by Divisadero Street Partners, L.P. (the "Fund"), which is a private investment fund managed by Divisadero Street Capital Management, LP (the "Adviser"), and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Divisadero Street Capital, LLC (the "Adviser GP"), the general partner of the Adviser, (iii) Divisadero Street Partners GP, LLC (the "Fund GP"), the general partner of the Fund, and (iv) William Zolezzi, the manager of both the Adviser GP and the Fund GP.
• F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.6705 - $24.8293. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.